Latest Information

  • Corporate Information

    Corporate Information

    From enabling the manufacturing of biopharmaceuticals to developing its own drug pipeline.

    Read PDF
  • Prometic secures additional USD $10 million (CAD $13.2 million) tranche from structured Alpha LP, an affiliate of Thomvest asset management

    Prometic secures additional USD $10 million (CAD $13.2 million) tranche from structured Alpha LP, an affiliate of Thomvest asset management

    Prometic announced today that it has secured an additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP (“SALP”), an affiliate of Thomvest Asset Management Inc.

    Read Article
  • Prometic retains investment bank for strategic transactions

    Prometic retains investment bank for strategic transactions

    Prometic announced that it has engaged Lazard to review and execute key strategic transactions for the Corporation.

    Read Article
  • Annual Information Form 2017

    Annual Information Form 2017

    Prometic Annual Information Form 2017

    Read PDF
  • Press Releases

    Read More
  • Quarterly Report Q2 2018

    Quarterly Report Q2 2018

    Read PDF
  • Quarterly Report Q1 2018

    Quarterly Report Q1 2018

    Prometic reports its 2018 first quarter highlights and financial results

    Read PDF
  • Corporate Governance and Nominating Committee Charter 2017

    Corporate Governance and Nominating Committee Charter 2017

    Read PDF
  • Financial Reports

    Read Now
  • Board of Directors Charter 2017

    Board of Directors Charter 2017

    Read PDF
  • Audit, Risk and Finance Committee Charter 2017

    Audit, Risk and Finance Committee Charter 2017

    Read PDF
  • Chairman Mandate 2018

    Chairman Mandate 2018

    Read PDF
  • Code of Ethics and Business Conduct 2017

    Code of Ethics and Business Conduct 2017

    Full detailed breakdown of Prometics Code of Ethics and Business Conduct for 2017 including details on regulatory compliance.

    Read PDF
  • Virtual Tour of Prometic Life Science's Manufacturing Process6:14

    Virtual Tour of Prometic Life Science's Manufacturing Process

    Watch Video
  • Corporate Governance

    Read More
  • Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency2:17

    Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

    At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).

    Watch Video
  • PLI Share Price

    View Now
  • Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment1:41

    Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment

    Prometic Life Science's senior director details the promising efficacy PBI-4050 alone or in combination with nintedanib demonstrated for treatment of IPF, suggesting the potential as an antifibrotic,

    Watch Video
  • ×

    Subscribe to our mailing list and be the first to know

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Prometic’s web site is subject to Prometic’s Privacy Policy including the fact that Prometic may transfer your personal information collected in connection with your registration on this website to its affiliates globally and to third party entities that provide services to Prometic. The data you have provided will be used for Prometic Life Sciences Inc. to send you information related to news and updates on the corporation and its subsidiaries.
     
    !
    Thank you!
    Error - something went wrong!
  • loading
    Loading More...